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Summary
Background: Cryoglobulinaemic vasculitis (CV) is a lymphoproliferative disorder
related to hepatitis C virus (HCV) infection; anti‐viral therapy is the first therapeutic
option. CV can be incapacitating, compromising the patients’ quality of life (QoL). In
a controlled study, interferon‐based therapy was associated with a lower virological
response in vasculitic patients than in patients without vasculitis. Limited, uncon-
trolled data on direct‐acting anti‐virals are available.
Aim: To evaluate safety, clinical efficacy, virological response and the impact of
interferon‐free treatment on QoL in HCV patients with and without mixed cryoglob-
ulinaemia (MC).
Methods: We prospectively studied HCV patients with cryoglobulinaemia (with vas-
culitis‐CV‐ and without vasculitis‐MC‐) and without cryoglobulinaemia (controls),
treated with direct‐acting anti‐virals. Hepato‐virological parameters, CV clinical
response and impact on QoL were assessed.
Results: One hundred and eighty‐two HCV patients were recruited (85 with CV, 54
with MC and 43 controls). A sustained virological response at 12 weeks (SVR12) was
achieved in 166 (91.2%) patients (77/85 CV, 48/54 MC, 41/43 controls). In CV SVR
patients, cryocrit levels progressively decreased and clinical response progressively
improved, reaching 96.7%, 24 weeks after treatment. QoL, baseline physical and men-
tal component summaries were lower in the CV group compared to the other groups
(P < 0.05). Scores improved in all groups, and significantly in CV patients after SVR.
Conclusions: No significant differences in SVR rates were recorded between cryo-
globulinaemic patients and controls and a high clinical and immunological efficacy
was confirmed in CV, supporting the role of interferon‐free therapy as the first ther-
apeutic option. Interestingly, CV patients had worse baseline QoL than other HCV‐
positive groups and interferon‐free therapy was effective in significantly increasing
QoL, suggesting the important role of direct‐acting anti‐viral‐based therapy in
improving CV's individual and social burden.
The Handling Editor for this article was Professor Grace Wong, and it was accepted for
publication after full peer-review.
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1 | INTRODUCTION
Hepatitis C virus (HCV) infection is considered a systemic disease,1,2
frequently including lymphoproliferative disorders, mostly mixed
cryoglobulinaemia (MC) and more rarely non‐Hodgkin's lymphoma.3-6
80%‐90% of MC patients are HCV‐positive and a percentage ranging
from 40% to 60% of HCV patients show cryoglobulinaemia; within
patients with cryoglobulinaemia, 5%‐30% develop symptomatic MC
vasculitis (CV), also called MC syndrome.4,5 Although CV is consid-
ered benign, it can lead to many complications, sometimes severe,
which can affect the patient's quality of life.7-11
Aetiological therapy is the first‐line option in HCV‐CV patients
and, for the past 15 y, pegylated‐interferon (Peg‐IFN) coupled with
ribavirin (RBV) has represented the standard of care.10,12-14 In the
majority of cases, viral eradication leads to CV clinical remission.2,13-15
The treatment of HCV infection experienced an important advance-
ment with the introduction of new direct‐acting anti‐virals (DAAs),
allowing IFN‐free regimens, shorter treatments and minimising side
effects.16-18 Data regarding these new IFN‐free regimens for the
treatment of CV patients are still limited, and based on uncontrolled
studies and short follow‐ups. These studies are generally consistent
with high rates of symptom remission in patients with sustained viro-
logical response (SVR), as well as a high tolerance of therapy.19-25
HCV was shown to have a tremendous impact on patient‐
reported outcomes, such as health‐related quality of life (HQoL) and
fatigue.26,27 The value of IFN‐free regimens in modifying such a neg-
ative impact can be fully appreciated by combining clinical outcomes
and patient‐reported outcomes.28,29 Some extra‐hepatic conditions
such as CV could greatly affect HQoL, and the effect of treatment
on this aspect of the disease should be considered as an important
part of the therapy outcome.30
To our knowledge, this is the first prospective, controlled study
evaluating patients with CV, patients with circulating cryoglobulins
without vasculitis (MC) and patients with no evidence of MC/CV or
other lymphoproliferative disorders (HCV controls), before, during
and after treatment with IFN‐free DAA regimens. Safety, clinical effi-
cacy, virological response and the impact of treatment on HQoL
were compared and evaluated among the 3 different groups of
HCV‐infected subjects.
2 | PATIENTS AND METHODS
2.1 | Patients
Between January 2015 and March 2016, we enrolled consecutive
patients with detectable levels of serum HCV‐RNA and eligibility for
IFN‐free anti‐viral treatment, at the out‐patient clinic of the Interde-
partmental Center for Systemic Manifestations of Hepatitis Viruses
(MaSVE), University of Florence, Florence, Italy, according to previ-
ously described inclusion criteria.13
The study included 3 different patient groups: Group “CV”: HCV
patients with cryoglobulinaemic vasculitis; Group “MC”: HCV
patients with circulating cryoglobulins without symptoms; Group
“HCV”: patients without CV, cryoglobulins or any other autoim-
mune/lymphoproliferative disorders. Subjects with uncertain classifi-
cation were excluded from the study. Exclusion criteria also included
co‐infection with HIV or HBV, presence of severe comorbidities not
related to MC (ie hepatocellular carcinoma) and the administration of
rituximab or plasma exchange cycles during the 24 weeks prior to
the study. Patients taking low‐medium doses of corticosteroids (0.1‐
0.5 mg/kg/d) or symptomatic drugs/measures (ie colchicine/low anti-
gen diet) were included. Demographical information, treatment his-
tory, HCV genotype data and laboratory evaluations were obtained
from the records of the MaSVE out‐patient clinic.
2.2 | Ethical guidelines
The study was conducted according to the 1975 Declaration of Hel-
sinki; all treatments were open‐label and therefore ethical approval
was not required for administration, when provided by the National
Health Care System. Therapy administered for compassionate use
required individual approval (named patient programme) by the insti-
tutional review board.
The study received institutional review board approval (evalua-
tion code: SPE 14.084_ AOUC); informed consent was obtained
from all patients.
2.3 | Treatment
Patients were treated with IFN‐free DAA combinations (Table 1)
according to the recommendations of the European Association for
the Study of the Liver,31 on which the Italian Association for the
Study of the Liver and the Italian Medicines Agency guidelines are
based, and were partly administered on compassionate use.
2.4 | Laboratory and clinical assessments
All evaluations were performed at baseline, at week 4 of treatment,
at the end of treatment (EOT) and at weeks 12 and 24 of the post‐
therapy follow‐up.
2.4.1 | Hepato‐virological laboratory and clinical
parameters
HCV infection was diagnosed by detecting serum HCV‐RNA (AMPLI-
COR® HCV Test, v2.0, Roche Diagnostics, Alameda, CA, USA). HCV
genotype was determined by a diagnostic test (VERSANT HCV
Genotype 2.0, Siemens Healthcare Diagnostics, Deerfield, IL, USA).
Liver‐related biochemical parameters (alanine aminotransferase,
aspartate aminotransferase, total and direct bilirubin) were also eval-
uated through routine tests.
Liver disease stage was assessed by non‐invasive methods
including liver elastography using FibroScan (Echosens, Paris, France),
imaging, clinical presentation and laboratory data; the METAVIR
score and Child‐Pugh scoring system for cirrhotic patients were used
to assess the severity of liver damage.
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2.4.2 | MC laboratory and clinical parameters
To assess MC diagnosis, circulating cryoglobulins were determined in
at least 3 metachronous samples.32 The percentage of packed cryo-
globulins in the serum, the cryocrit, was assessed following the same
time‐points as the other laboratory evaluations. The other immuno-
logical parameters for evaluating MC response (measurement of the
C4 complement fraction and rheumatoid factor [RF]) were performed
as routine diagnostic tests.
Estimated glomerular filtration rate (eGFR) was calculated with
the MDRD GFR equation, based on creatinine and patient character-
istics.
Clinical evaluation of CV was performed at EOT and at weeks
12 and 24 of the post‐therapy follow‐up in relation to previous stud-
ies33 and to the current classification criteria.5,34-36
In detail, purpura was assessed as previously shown33 with minor
modifications and classified according to 4 semi‐quantitative grades:
0 (no purpura), + (limited or fluctuating involvement of the lower
limbs), ++ (diffuse and persistent involvement of the lower limbs),
+++ (diffuse and persistent involvement of the trunk and the lower
limbs); leg ulcer response was considered as complete when all the
ulcers completely healed, as improved with a reduction of at least
25% in diameter and as no response with the reduction of less than
25% in ulcer diameter, or if they worsened.
Arthralgia, weakness and sicca syndrome were measured through
a patient‐scored Visual Analog Scale (VAS) (range, 0‐100); treatment
response was defined as follows: complete (disappearance of symp-
tom/s), improvement (at least 25% VAS reduction), no response (less
than 25% VAS reduction or worsening). Neuropathic symptoms,
including both paraesthesias/pain and clinically evident motor deficit,
TABLE 1 Main demographical, hepatovirological and clinical baseline characteristics of 182 HCV patients stratified in the 3 study groups
HCV‐ctrs (n = 43) MC (n = 54) CV (n = 85) P
Age (y)b 59.8 (±1.73) 60.4 (±1.7) 65 (±1) 0.0084 HCV‐ctrs vs CV
0.0254 MC vs CV
Gender (male/female) 25/18 30/24 29/56 0.0066 HCV‐ctrs vs CV
0.0088 MC vs CV
Metavir scorea
F0‐F1 0 0 33
F2 0 0 7
F3 19 23 5
F4 24 31 40
Child‐Pugh score (A/B/C) 20/4/0 29/2/0 29/10/1
ALT (U/L)b 105 (±12) 120.4 (±10) 84.3 (±8) 0.0430 MC vs CV
AST (U/L)c 76.3 (±7.8) 94 (±8) 73 (±9.1) NS
Bilirubin Totd 0.88 (±0.07) 0.94 (±0.05) 0.8 (±0.04) 0.02 MC vs CV
Bilirubin Dire 0.33 (±0.04) 0.32 (±0.02) 0.29 (±0.04) NS
HCV‐RNA (IU/mL × 106) 2.4 (±0.38) 2.7 (±0.48) 2.9 (±0.43) NS
HCV genotype
1a 6 (13.95%) 8 (14.8%) 8 (9.4%)
1b 25 (58%) 33 (61.1%) 48 (56.5%)
2 6 (13.95%) 4 (7.4%) 18 (21.2%)
3 3 (7%) 7 (13%) 7 (8.2%)
4 3 (7%) 2 (3.7%) 2 (2.35%)
Mixed (1b+2) — — 2 (2.35%)
Previous AVT response
Naïve 24 25 46
Experienced 19 29 39
DAA treatment
3Df 8 13 16
3D+RBV 1 5 4
Sofosbuvir+Daclatasvir 4 2 9
Sofosbuvir+Daclatasvir+RBV 5 11 7
Sofosbuvir+Ledipasvir 6 8 12
(Continues)
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were also assessed by VAS and, when possible, by electromyographi-
cal analysis. Kidney function was evaluated according to serum crea-
tinine and urinalysis with the evaluation of proteinuria. A complete
response was defined as a combination of normalisation of renal
function when abnormal (serum creatinine) and proteinuria of 0.5 g/d
or less. An improvement was defined as stable or ameliorated renal
function, and/or persisting for at least a 50% reduction of protein-
uria. No response was defined as worsening of renal function not
attributable to different causes and/or proteinuria increase or persis-
tence higher than 0.5 g/d.
Raynaud phenomenon response was evaluated considering the
attack number in a 2‐week period and severity according to the VAS
scale (0‐100), as previously suggested.36 On this basis, we consid-
ered the disappearance of attacks as a complete response, the
reduction of at least 30% frequency and severity of the attacks as
an improvement and, a reduction of less than 30% as a non‐
response.
2.5 | Efficacy assessments
SVR was defined as an undetectable serum HCV‐RNA at week 12
(SVR12) after therapy cessation; a HCV‐RNA evaluation was per-
formed at week 24 of the post‐treatment follow‐up (SVR24).
Clinical and immunological response was assessed following pre-
viously used criteria.22,37 Briefly, we considered “full‐complete
responders” patients with the disappearance of all baseline symp-
toms, and “complete responders” those with improvement of all the
baseline symptoms, “partial responders” those with the disappear-
ance or improvement of at least half of the baseline symptoms, and
“non‐responders” patients with the disappearance or improvement
of fewer than half of the baseline symptoms.
MC immunological response was “complete” in the case of the
disappearance of cryoglobulins, “partial” for a decrease of cryocrit to
<50% of baseline level, and “null” in all other cases, following previ-
ously accepted criteria.22,37
2.6 | Measurements and analysis of the HQoL
Patients were interviewed with a patient‐reported outcome ques-
tionnaire at baseline, EOT and at weeks 12 and 24 of the post‐treat-
ment follow‐up; we focused on a widely used generic/validated
instrument for HQoL evaluation, the Short Form‐36 version 2 (SF‐
36v2).38 It assesses 8 HQoL scales (scores ranging from 0 to 100
with higher values corresponding to better health status): physical
functioning, role physical, bodily pain, general health, vitality, social
functioning, role emotional and mental health along with 2 summary
scores summarising the physical (physical component summary score
[PCS]) and mental health (mental component summary score [MCS])
components of SF‐36.39
2.7 | Safety assessment
Patients were monitored for the occurrence of adverse events (AEs)
during regularly scheduled check‐ups and additional unscheduled
appointments were made to ascertain the presence and/or the sever-
ity of the AE reported by telephone.
2.8 | Statistical analysis
Quantitative variables were analysed using one‐way analysis of vari-
ance (nonparametric ANOVA) or with t test for unpaired samples.
Categorical variables were analysed with the χ2 test and Fisher's
TABLE 1 (Continued)
HCV‐ctrs (n = 43) MC (n = 54) CV (n = 85) P
Sofosbuvir+Ledipasvir+RBV 9 5 7
Sofosbuvir+Simeprevir 5 3 7
Sofosbuvir+Simeprevir+RBV 1 2 —
Sofosbuvir+RBV 4 5 23
Laboratory
Cryocrit (%) 0 1.2 (±0.2) 3.7 (±0.8) 0.0017 MC vs CV
RFg 19.8 (±0.7) 20.5 (±1.7) 221(±107) 0.0026 HCV‐ctrs vs CV
0.026 MC vs CV
C4h 0.20 (±0.03) 0.15 (±0.02) 0.09 (±0.008) 0.0007 HCV‐ctrs vs CV
0.0057 MC vs CV
HCV‐ctrs, HCV controls; MC, mixed cryoglobulinaemia without vasculitis; CV, cryoglobulinaemic vasculitis; AVT, anti‐viral treatment. Data are expressed
as mean ± standard error.
aBased on liver stiffness assessed by FibroScan.
bAlanine aminotransferase (ALT) normal range: 12‐65 U/L.
cAspartate aminotransferase (AST) normal range: 15‐37 U/L.
dTotal bilirubin normal range: 0.2‐1 mg/dL.
eDirect bilirubin normal range: 0‐0.2 mg/dL.
f3D: ombitasvir, paritaprevir+ritonavir, dasabuvir.
gRheumatoid factor (RF) normal values: <20 IU/mL.
hC4 normal values: 0.1‐0.4 g/L.
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exact test when necessary. All tests were two‐sided at a 0.05 signifi-
cance level. Analyses were performed by Stata v.9.0 (StataCorpLP,
College Station, TX, USA). Scores were obtained from the SF‐36v2
questionnaire from dedicated software and then statistical analysis
was performed.
3 | RESULTS
From January 2015 to March 2016, 182 consecutive HCV‐infected
patients (84 males and 98 females, mean age 63 ± 0.84 years)
matched the inclusion criteria and were prospectively enrolled in the
study. Twenty‐six patients were treated on a compassionate basis,
while drugs were provided for the others by the national health care
system. Among the 182 HCV‐positive patients, 139 (76%) had circu-
lating cryoglobulins, 85/139 (61%) with symptoms/vasculitis (CV) and
54 (39%) without symptoms (MC). The remaining 43/182 (24%) sub-
jects displayed no evidence of signs/symptoms of MC (pathological
controls “HCV‐ctrs”). Among the CV group, 14 of 85 subjects were
included in a previous uncontrolled study.22 The flow chart of the 3
study groups is reported in Data S1. The main baseline demographi-
cal, clinical and virological characteristics of the study population are
reported in Table 1. The groups were homogeneous for the majority
of the characteristics and parameters we evaluated, with, as
expected, higher mean age and number of women in the CV popula-
tion compared to the other groups (Table 1); in addition, the Italian
criteria of DAA eligibility at the time of enrolment permitted us to
treat F0‐F2 patients only when clinically significant mixed cryoglobu-
linaemia or lymphoma was diagnosed and, therefore, some liver‐
related parameters resulted as less altered in patients belonging to
the CV group compared to the others (Table 1).
DAA‐based IFN‐free regimens were administered combined with
RBV in 20/43 (46.5%) HCV‐ctrs, in 28/54 (52%) MC patients and in
59/85 (69%) CV patients.
All but 3 patients reached EOT; among the 179 patients who
completed the treatment, 6 experienced a relapse by week 4 of the
post‐therapy follow‐up.
Patients were followed up for a median of 16.4 months (range 9‐
23) after the completion of therapy.
As a further 7 patients were lost to follow‐up after the EOT, 166
patients (41/43 HCV‐ctrs; 48/54 MC; 77/85 CV) were monitored
until at least week 24 after the EOT.
3.1 | Virological and hepatological response
An “intention to treat” analysis was possible on 182 patients and a
“per protocol analysis” on 179 patients in regard to virological out-
come.
Following the intention to treat analysis, SVR12, confirmed by
SVR24, was obtained in 166 (91.2%) patients, and stratified as fol-
lows: 41/43 (95.3%), 48/54 (88.9%) and 77/85 (90.6%) from the
HCV‐ctrs, the MC and the CV groups respectively. The per protocol
analysis showed a SVR12 rate of 92.7%, stratified as follows: 41/42
(97.6%), 48/54 (88.9%) and 77/83 (92.8%) from the HCV‐ctrs, the
MC and the CV groups respectively.
Three patients interrupted treatment (Table 2). One CV patient
was hospitalised for the appearance of jaundice during therapy;
another patient, with severe CV, voluntarily interrupted treatment
reporting a subjective worsening of a previous sensorimotor neu-
ropathy not supported by 2 different neurological check‐ups. The
last patient interrupted therapy at week 9 when she underwent a
liver transplant (Table 2); to note, this patient remained HCV‐RNA
negative after the liver transplant.
Among the 6 patients who relapsed by week 4 of the post‐ther-
apy follow‐up, 1 poly‐transfused patient was identified with an
unrecognised mixed genotype infection (genotype 1b+2, Table 2)
and responded to a second treatment tailored for genotype 2 (data
not shown). All the other patients tested as negative in the test for







of therapy Reason of treatment failure
1 53/M HCV‐ctrs 4 F4 N SOF+SMV+RBV/12 Relapse at week 4 of follow‐up
2 59/M MC 4 F4 I SOF+LED/24 Relapse at week 4 of follow‐up
3 76/F MC 1b F3 I SOF+LED/12 Relapse at week 4 of follow‐up
4 70/F CV 1b F3/F4 I 3D/12 Relapse at week 4 of follow‐up
5 58/M CV 1a F4 N SOF+RBV/48 Relapse at week 4 of follow‐up
6 43/M CV 1b+2 F3 N 3D+RBV/24 Apparent relapse, unrecognised
mixed genotype infection
7 69/F CV 1b F4 N 3D/24 Interruption for hyperbilirubinaemia at week 1
8 56/F CV 1b F1/F2 I 3D/24 Voluntary interruptiona at week 4
9 49/F HCV‐ctrs 1a F4 N 3D/24 Interruption due to liver transplantb
HCV‐ctrs, HCV controls; MC, mixed cryoglobulinaemia without vasculitis; CV, cryoglobulinaemic vasculitis. The stage of liver disease is expressed by
METAVIR score; N, treatment naïve; I, interruption of IFN‐based treatment for intolerance; SOF, sofosvubir; SMV, simeprevir; LED, ledipasvir; RBV,
ribavirin; 3D, ombitasvir, paritaprevir+ritonavir, dasabuvir.
aThe patient voluntarily interrupted treatment after 4 wk reporting a subjective worsening of a previous sensorimotor neuropathy.
bThis patient interrupted treatment at week 9 due to a liver transplant, and maintained a negative viraemia.
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resistance‐associated variants (NS3, NS5A or NS5B variants, depend-
ing on the drug combination).
According to previously published results,22,23 of the 166
patients who completed the post‐therapy follow‐up, the available
liver function parameters showed an overall improvement (Table S1).
3.2 | CV clinical response
The 77 CV patients who experienced SVR24 were evaluated for clin-
ical response at different time points of the post therapy follow‐up
(Figure 1). At EOT, 1.7%, 56.7%, 23.3% and 18.3% of CV patients
were full complete‐, complete‐, partial‐, and non‐responders respec-
tively. Improvement was evident at SVR12 with 20.7%, 43.1%,
29.3% and 6.9% full complete‐, complete‐, partial‐ and nonrespon-
ders respectively. At SVR24 clinical efficacy further increased with
25% and 60% of CV patients experiencing a full‐complete response
and a complete response, respectively, while the percentage of par-
tial responders decreased to 11.7% and to 3.3% for the nonrespon-
ders.
CV SVR patients were stratified, according to baseline severity,
in patients with (1) mild/moderate manifestations (66/77) and (2)
with severe manifestations (11/77), as recently stated.14
Pre‐therapy grade b severity was characterised as 3/3 (100%) for
clinical nonresponders, 6/9 (67, 7%) for partial‐responders, 1/46 (2%)
for complete responders, and 1/19 (5.3%) for full‐complete clinical
response.
A total of 7/85 CV patients did not achieve SVR and clinical
response; these included 3 patients with severe CV: a patient with
severe sensorimotor neuropathy with a history of CNS involvement
(transient ischaemic attack‐like syndrome) and who interrupted
treatment early, and 2 with rapidly progressive glomerulonephritis
previously treated with rituximab (Table 2), including a case of viro-
logical relapse after transient response. In the latter case, kidney
function, was moderately reduced before and after treatment
(chronic kidney disease stage 3B), after the recurrence of HCV repli-
cation rapidly worsened (chronic kidney disease stage 5, requiring
haemodialysis).
Among the 85 CV patients who initiated treatment, the 3
patients with grade C severity14 had to be included in the virological
failure group (2 of them interrupted therapy and 1 experienced a
virological relapse, Table 2).
The behaviour of the main symptoms is reported in Table 3. In
accordance with previous reports,22 we noted that while the
improvement of some symptoms was rapid (ie purpura and skin
ulcers), others such as fatigue, sicca syndrome and peripheral neu-
ropathy were slow to respond (Table 3).
The behaviour of eGFR in the 9 HCV‐CV patients with kidney
involvement who reached an SVR and completed the follow‐up until
SVR24 are reported in Table S2. None of these patients had baseline

























F IGURE 1 Clinical response of patients with cryoglobulinaemic
vasculitis. FCR: full complete responders; CR, complete responders;
PR, partial responders; NR, nonresponders; EOT, end of treatment;
SVR, sustained virological response
TABLE 3 Behaviour of the main CV symptoms after therapy in CV patients who achieved viral eradication




















Purpura 58 36 (62%) 5 (9%) 17 (29%) 46 (79%) 2 (3%) 10 (17%) 48 (83%) 5 (9%) 5 (9%)
Arthralgias 41 12 (29%) 12 (29%) 17 (41%) 14 (34%) 7 (17%) 20 (49%) 12 (29%) 12 (29%) 17 (41%)
Weakness 52 11 (21%) 16 (31%) 25 (48%) 14 (27%) 18 (35%) 20 (38%) 19 (37%) 20 (38%) 13 (25%)
Peripheral
neuropathy
37 6 (16%) 10 (27%) 21 (57%) 16 (43%) 7 (19%) 14 (38%) 18 (49%) 6 (16%) 13 (35%)
Raynaud
phenomenon
17 9 (53%) 2 (12%) 6 (35%) 10 (59%) 1 (6%) 6 (35%) 13 (76%) 1 (6%) 3 (18%)
Sicca
syndrome
34 12 (35%) 14 (41%) 8 (24%) 11 (32%) 15 (44%) 8 (24%) 10 (29%) 15 (44%) 9 (26%)
Ulcer 7 1 (14%) 1 (14%) 5 (71%) 5 (71%) 1 (14%) 1 (14%) 7 (100%) — —
Proteinuria 9 1 (11%) 1 (11%) 7 (78%) 3 (33%) 1 (11%) 5 (56%) 3 (33%) — 6 (67%)
CV, cryoglobulinaemic vasculitis; BSL, baseline; EOT, end of treatment; SVR, sustained virological response.
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in some cases there was a light decrease in eGFR during and after
treatment, while SVR24 eGFR levels were maintained or slightly
increased compared to baseline values.
During the post‐therapy follow‐up, no patients died or developed
haematological malignancies.
3.3 | Immunological response
The mean cryocrit progressively decreased in MC patients from
1.2 ± 0.2 at baseline to EOT (0.63 ± 0.12), slightly increased at
SVR12 (0.65 ± 0.15) and lowered significantly at SVR24
(0.45 ± 0.14; P < 0.05 compared to baseline and to week 4) (Fig-
ure S2, panel A). The immunological response at SVR12 was com-
plete in 39.4% of cases, partial in 18.2%, and null in 42.4% of
patients. At SVR24 there were about 76% responders (66.7% com-
plete 9% partial responders) versus 24.3% null responders. The levels
of serum RF slightly decreased and C4 complement component
slightly increased from baseline to SVR24 in MC patients (Figure S2,
panels B and C).
Regarding the CV group, the baseline cryocrit levels were higher
than those observed in the MC group, with a mean value of
3.7 ± 0.8 (range 38‐1.5), which halved rapidly at week 4 of treat-
ment (1.65 ± 0.3; P < 0.001 vs baseline), and progressively
decreased until SVR24 (Figure S3, panel A). The immunological
response was complete, partial and null at SVR12, in 46.2%, 32.3%
and 21.5% of cases respectively. At SVR24, the percentage of CV
patients with a complete immunological response increased to
69.2% while partial and null response both decreased to 18.5% and
12.3% respectively.
The serum RF and C4 values rapidly and significantly improved
during treatment and the post‐therapy follow‐up (Figure S3, panels B
and C).
3.4 | Evaluation of HQoL
HQoL evaluation was available for 15/41 HCV‐ctrs, 18/48 MC and
26/77 CV patients. The scores of the 8 items related to SF‐36, strati-
fied for each group and collected at EOT, SVR12 and SVR24, are
provided in Table S3. Considering the single items, improvement
reached significance for some items solely in the CV patient group
(Table S3).
The behaviour of the 2 summary scores PCS and MCS, calcu-
lated at the same points in time, for the 3 studied populations, is
reported in Figure 2.
At baseline, CV patients were characterised by a more consider-
able impairment in both scores (PCS: 51 ± 4; MCS: 55.2 ± 3.4) com-
pared to HCV‐ctrs (PCS: 68.5 ± 10; MCS: 68.2 ± 4.7) and MC (PCS:
69.2 ± 6; MCS: 66 ± 7.2) patients (CV PCS vs HCV‐ctrs PCS:
P < 0.05; CV PCS vs MC PCS: P < 0.01; CV MCS vs HCV‐ctrs MCS:
P < 0.05). In all 3 groups, we observed a decrease in MCS and PCS
at the EOT as well as a gradual increase in the 2 scores during the
post‐therapy follow‐up (Figure 2).
3.5 | Treatment safety
Among the 182 patients who initiated DAA therapy, AEs occurred in
99 (54.4%); stratifying for the 3 study groups, AEs were reported by
15/43 (34.9%) HCV patients, by 27/54 (50%) MC patients and by 57/
85 (67%) CV patients. On the whole, 26/182 subjects experienced
more than 1 AE. As shown in detail in Table S4, the most frequent
AE was anaemia, which was related to ribavirin administration. In
the majority of cases, the decrease in haemoglobin required an inter-
vention (Table S4), even if a blood transfusion was not needed in
any instance.
One case of hyperbilirubinaemia was the most severe AE and
the only one requiring therapy interruption and hospitalisation. As
previously mentioned, this patient discontinued treatment after
1 week of administration as the total bilirubin score reached 24 mg/
dL (normal range 0.2‐1 mg/dL). A patient complained of worsening
neuropathy and voluntarily interrupted therapy; however, as previ-
ously mentioned, electroneurography and 2 different neurological
consultations did not find any evidence of such worsening.
All the other AEs, reported in Table S4, were mild and usually
well tolerated.
4 | DISCUSSION
To our knowledge, this is the first prospective and controlled analy-
sis of DAA‐treated patients with HCV‐related cryoglobulinaemia,
either symptomatic (CV) or asymptomatic (MC). As described in a
study performed in the IFN‐based era,13 controls (HCV‐ctrs) were
represented by HCV patients without cryoglobulinaemia or other
autoimmune/lymphoproliferative disorders. We evaluated virological
and clinical‐immunological response and the effect of treatment on
the HQoL in these HCV‐patient subsets, consecutively treated with
IFN‐free therapy.
According to previous results and well‐known demographical
characteristics of mixed cryoglobulinaemia subjects,13 CV patients
were older and with a female over‐representation compared to MC
and HCV‐ctrs groups. Conversely, the less severe degree of liver dis-
ease in CV than in patients without vasculitis observed in this study,
but not in other reports,13 was probably influenced by the Italian cri-
teria of DAA eligibility at the time of enrolment. This allowed us to
only treat patients with severe liver damage (≥F3) with the excep-
tion of patients with clinically significant mixed cryoglobulinaemia,
(or lymphoma), even with mild/absent liver fibrosis. A previous con-
trolled analysis in similar patient categories, treated with peg‐IFN
and RBV, showed a significant difference in the rate of SVR between
HCV‐ctrs and both MC and CV groups.13 Thus, the presence of
cryoglobulinaemia was a prognostic factor of non‐response indepen-
dent from the severity of liver disease, or other well‐known prognos-
tic factors.13 In this study, both intention to treat and per protocol
analyses confirmed the excellent virological outcome reported by
previous studies on CV or MC patients treated with DAAs,20,22-25,40
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hindering a valuable logistic regression analysis to identify outcome
predictors. In other words, using DAAs, it was not possible to find
significant differences in SVR rates between cryoglobulinaemic
patients and controls. However, we observed that the few cases of
treatment failure (patients who interrupted treatment or relapsed)
generally belonged to the MC or CV groups and were advanced
cases; interestingly, in one of the cases, with kidney involvement,
viral relapse was followed by a consistent worsening of the cryo-
globulinaemic nephropathy. This appears to be in agreement with
the study by Kondo et al., where the incidence of treatment discon-
tinuation among patients with chronic kidney disease was signifi-
cantly higher than that among patients without renal damage.41 In
our study, among patients with renal involvement experiencing viral
eradication, we did not observe a persistent worsening of eGFR. In
detail, CV patients with renal involvement (baseline eGFR>30) who
reached week 24 of post‐therapy follow‐up maintained or slightly
improved the pre‐treatment eGFR levels. Longer follow‐ups will be
useful to ascertain the real effect of viral eradication on kidney dam-
age.
According to previous results,20,22,24 independent of the pres-
ence or absence of mixed cryoglobulinaemia, liver function parame-
ters showed an overall improvement in all SVR patients.
We observed a high rate of improvement of CV clinical indices
following the virological responses (85% considering both full com-
plete/complete response), which went on improving during a longer
follow‐up. However, patients with severe manifestations had a
worse clinical outcome during the mid‐term post‐therapy follow‐up.
All the patients who did not experience clinical improvement and a
relevant percentage of partial responders had grade b CV severity,14
and all 3 patients with grade c CV experienced both virological and
clinical failure. Conversely, a full complete clinical response was
recorded in only 1 grade b patient. This is in accordance with obser-
vations by Emery et al.24 that reviewed 18 HCV patients with symp-



















































































Physical Component Summary Score (PCS)























F IGURE 2 Behaviour of the 2 summary scores, physical component summary score (PCS) and mental component summary score (MCS), in
the 3 patient groups. (A) PCS in HCV patients without MC; (B) PCS in MC patients; (C) PCS in CV patients; (D) MCS in HCV patients without
MC; (E) MCS in MC patients; (F) MCS in CV patients; **P < 0.01 compared to baseline scores; °°P < 0.01 and °°°P < 0.001 compared to EOT
scores. HCV‐ctrs, HCV‐controls; CV, cryoglobulinaemic vasculitis; MC, mixed cryoglobulinaemia; EOT, end of treatment; SVR, sustained
virological response
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severe vasculitis. In particular, of 7 patients with mild‐moderate CV
and 7 patients with severe CV, 6 patients (85.7%) and 1 patient
(14.2%), respectively, achieved a complete clinical response. None of
the 4 patients with fulminant CV achieved a complete clinical
response at last follow‐up despite achievement of SVR12 in all
cases.
Altogether, data concerning both virological and clinical/immuno-
logical response suggest that there is an opportunity to treat cryo-
globulinaemic patients early preventing the evolution to severe
disease forms.
The finding of more altered immunological parameters in the CV
than in the MC group is consistent with previous reports13,23,24 and
suggests a minor involvement/activation of the immune system in
MC, possibly corresponding to an early disease stage. Emery et al.
showed a better immunological response in MC than CV patients,
even if the difference in clearing cryoglobulins was not significant.24
Similar data were described by Bonacci et al. reporting, for MC
patients, a cryoglobulin clearance of 62% and a complete immunologi-
cal response of 53% compared to 45% of cryoglobulin clearance and
43% of complete immunological response in CV patient reports.23
Our analysis partially confirmed these findings, even though we
observed a higher rate of complete immunological response in CV
patients. In SVR24 CV patients, the rate of complete immunological
response was lower than that of complete clinical response; this dis-
crepancy was previously reported.13,23,24,42 Longer follow‐ups will be
useful to assess the percentage of persistent CV stigmata.13
Results of particular interest were obtained by the comparative
HQoL evaluation among the 3 different groups of patients that was
performed using the SF‐36 questionnaire to obtain PCS and MCS
components through specific analysis. The potential impact on HQoL
of extra‐hepatic manifestations and its consequences on indirect
costs of HCV management were highlighted in a meta‐analysis by
Younossi et al.43 The French “VASCUVALDIC” study showed data
regarding increasing HQoL scores in 24 CV patients treated with
Sofosbuvir plus RBV, analysing the baseline values vs EOT and
SVR12.20 The authors reported a progressive improvement of scores
at EOT and SVR12. Conversely, considering the evolution of HQoL,
we observed a decrease in MCS and PCS at EOT in all 3 groups,
despite a gradual increase in the 2 scores during the post‐therapy
follow‐up. Conceivably this could have been caused by side effects
induced by RBV administration in the majority of patients who
underwent the SF‐36 interview. Even if side effects were generally
mild and well tolerated, they could have had a negative impact on
aspects of everyday life. The HQoL decline was transient and the
benefits on physical and emotional states were evident from SVR12.
To the best of our knowledge, no previous comparative analyses on
HQoL between CV vs non‐CV HCV patients were available. We
could show for the first time that patients with CV had lower PCS
and MCS before treatment and, therefore, a worse HQoL, compared
to MC and HCV‐ctrs. Using a scientifically validated questionnaire,
we were able to confirm our previous observations stemming from
clinical practice. Even if the improvement of PCS and MCS was clear
in all 3 groups, for CV patients the SVR12 and SVR24 values were
significantly higher, compared to baseline scores. This means that
DAA treatment could be highly beneficial for CV patients regarding
HQoL, which is an important goal of therapy. These aspects, taken
into account by pharmacoeconomic analyses, seem to have impor-
tant implications on public expenditure, not only through direct med-
ical costs but also through indirect costs due to decreased work
productivity. This represents a relevant issue especially in countries
with a high prevalence of HCV.27,44
Regarding therapy safety and tolerance, all the AEs were gener-
ally mild and well tolerated; however, we recorded a higher percent-
age of AEs in MC and CV than in HCV‐ctrs. This is in accordance
with a large controlled study performed on CV, MC and HCV‐ctrs
patients in the era of IFN‐based therapy,13 suggesting the key role
played by RBV use in influencing the observed differences. The per-
centage of AEs in the CV group (57%) was very similar to the one
reported by other authors.13,20,23
In summary, our prospective/controlled analysis, including a wide
population of cryoglobulinaemic patients, confirmed the high efficacy
and safety of DAAs in patients with HCV‐related cryoglobulinaemia.
The high SVR rates did not allow for a multivariate logistic regres-
sion analysis and no statistical differences in SVR rates were
observed. However, patients who interrupted treatment or relapsed
were mostly those with cryoglobulinaemia and with advanced, long‐
lasting vasculitis. Similar correlations were observed concerning the
CV clinical outcome; despite the remarkable success rate, patients
with severe CV did not experience a complete response. Collectively,
these data emphasise the need to identify cryoglobulinaemic patients
and to treat them as soon as possible to obtain the best virological
and clinical benefits. This is only feasible when a correct diagnostic
approach to HCV patients has been used, so as not to underestimate
the condition.45
More interestingly, this study shows that among patients with
chronic HCV infection, those with CV have significantly worse HQoL
and DAA therapy is effective in increasing both physical and mental
scores; this additional benefit of IFN‐free treatments should be taken
into account as an important goal of modern anti‐viral therapy.
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